Director Laura Tadvalkar resigns from Hemab Therapeutics board effective May 8, 2026

Hemab Therapeutics Holdings, Inc.

Laura Tadvalkar, Ph.D., resigned as a member of the Board, effective May 8, 2026.
Resignation not related to any disagreement with the Company on operations, policies or practices.
No replacement director announced; Board size reduced by one.

item 5.02

Source: SEC EDGAR

accession 0001193125-26-216699

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.